Abstracts

Exposure to Antiretrovirals (ARVs) and Development of Chronic Kidney Disease (CKD)

Background: Previous studies in persons with an initially normal eGFR have been underpowered to assess whether the incidence of CKD increases immediately after starting potentially nephrotoxic ARVs and then remains stable or continues to increase with duration of exposure. Methods: D:A:D study participants were followed from baseline until earliest of CKD, last eGFR, 1/1/2013 or…

High Efficacy of Daclatasvir/Asunaprevir/PR in HIV/HCV1-4 Null Responders (ANRS HC30)

Background: Few direct anti-HCV agents (DAAs) have been studied in difficult to treat HIV co-infected patients, in particular null responder and cirrhotic. Daclatasvir and Asunaprevir combined with pegylated interferon-ribavirin (PR) have shown promising results in HCV mono-infected patients. Methods: An open label, single arm, phase 2 study (ANRS HC30 QUADRIH) in HIV/HCV genotype (GT) 1…

High SVR Regardless of Time to Suppression With ABT-450/r/Ombitasvir & Dasabuvir+RBV

Background: SVR12 rates >90% have been achieved with the interferon-free 3 direct-acting antiviral regimen (3D) of co-formulated ABT-450 (identified by AbbVie and Enanta)/ritonavir/ombitasvir with dasabuvir +/- RBV in HCV genotype (GT) 1 mono-infected patients. We assessed HCV RNA viral suppression over time in HCV/HIV-1 co-infected patients treated with 3D+RBV and in mono-infected patients treated with…

Real-World Pharmaceutical Costs in the Simeprevir/Sofosbuvir Era: $164,485 per SVR4

Background: Pharmaceutical costs-per-sustained virologic response (SVR4) were determined for patients treated with simeprevir (SMV) and sofosbuvir (SOF) at a large metropolitan medical center. Methods: The SVR4 rate was calculated for 103 genotype 1 HCV-infected patients who started on SMV- SOF-containing regimens between 12/2013-6/2014. Advanced fibrosis/cirrhosis was defined as a FIB-4 score ≥ 3.25. Costs were…

Impact of Deferring HCV Treatment on Liver-Related Events in HIV+ Patients

Background: Successful treatment of HCV infections substantially reduces the risk of liver-related complications. However, cost considerations and the availability of better treatment options in the future often leads to the deferral of treatment of HCV infection in patients with limited liver fibrosis. In this study, we modelled the impact of different treatment strategies on liver…

Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study

Background: The pangenotypic, once-daily combination of daclatasvir (DCV) and sofosbuvir (SOF) achieves high rates of sustained virologic response (SVR) in patients with chronic HCV infection. DCV+SOF has favorable safety and drug-drug interaction profiles and a high barrier to resistance, supporting the phase 3 ALLY-2 study of DCV+SOF in patients with HIV/HCV coinfection. Methods: This randomized,…